QIAGEN Further Expands NGS Informatics Offerings
BIOBASE has more than 600 customers, according to QIAGEN. This is the third next-generation sequencing (NGS) informatics company QIAGEN has purchased, following the acquisitions last year of Ingenuity Systems (see IBO 4/30/13) and CLC bio (see IBO 10/31/13). Like Ingenuity, BIOBASE offers tertiary-analysis tools for NGS data.
Hilden, Germany and Germantown, MD 5/20/14—QIAGEN has acquired BIOBASE, a provider of expertly curated biological databases, for an undisclosed amount. BIOBASE products include the HGMD Human Gene Mutation Database on human inherited-disease mutations and the PGMD PharmacoGenomic Mutation Database, which identifies all published gene variants that affect patient drug response. “With HGMD and other content from BIOBASE, a respected organization with a dedicated team and robust line of unique databases and software, QIAGEN is further extending its competitive advantage as the overall market leader for clinical interpretation of human sequencing data,” stated QIAGEN CEO Peer M. Schatz. QIAGEN will market BIOBASE products on a standalone basis as well as integrate them into its Ingenuity Knowledge Base. BIOBASE CEO Michael Tysiak has joined QIAGEN as general manager of QIAGEN Wolfenbüttel, the new name of BIOBASE.
